Application of Maoeryisu for pharmacy

A technology of calyxine B and medicine, applied in the field of calyxine B, can solve the problem of inability to treat acute leukemia and the like

Inactive Publication Date: 2006-11-29
KUNMING INST OF BOTANY - CHINESE ACAD OF SCI +1
View PDF1 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But the drug doesn't treat diseases like acute leukemia and Burkitt's lymphoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Maoeryisu for pharmacy
  • Application of Maoeryisu for pharmacy
  • Application of Maoeryisu for pharmacy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] EriB inhibits growth and induces apoptosis in human leukemia cells

[0074] The effect of EriB on the growth of human hematologic malignancies was detected by MTT assay. The half-inhibition of growth of these cells by EriB was between 0.2-2 μM. Different concentrations of EriB have growth inhibitory effect on all tested cells. The half-inhibitory dose of EriB on Kasumi-1 cells was 0.2 μM, on NB4 and NB4 / R2 cells was 0.5 μM, and on NB4R1, HL60 and U937 cells was 1 μM. IC of Raji, Daudi and Jurkat cells in malignant lymphoproliferative disorders less sensitive to eillin than myeloid leukemia cells 50 Values ​​above 1.5 μM (see Figure 1B ).

[0075] Kasumi-1 cells are most sensitive to EriB, and EriB has a time- and dose-dependent inhibitory effect on cell growth (see Figure 1C left), the viability of the cells also decreased correspondingly (see Figure 1C right). Inhibitory effects were also observed at concentrations below 0.25 μM. After Kasumi-1 cells were tr...

Embodiment 2

[0079] Elein B disrupts mitochondria and activates caspase-3 at apoptosis-inducing concentrations

[0080] In order to study the ultrastructural changes of Kasumi-1 cells in the early stage of apoptosis and to search for hints of mechanisms involved in apoptosis, we performed transmission microscopy analysis. Normal tumor cell nuclei are irregular in shape and contain a large number of rough endoplasmic reticulum and mitochondria (see Figure 2B ), Kasumi-1 cells treated with EriB for 6 hours showed swollen cells, increased numbers of lysosomes, swollen and weakened mitochondria (see Figure 2B ), suggesting early apoptosis and mitochondrial damage (see Figure 2B ).

[0081]Kasumi-1 cells treated with EriB were incubated with Rh123 and used for flow cytometry detection, the results showed that the mitochondrial transmembrane potential decreased significantly, and there was a time and dose dependence (see Figure 2C ). In Kasumi-1, NB4 and NB4 / R2 cells, the cleavage of cas...

Embodiment 3

[0083] Bcl-2 and Bcl-X via down-regulation of Bcl-2 L Acts on the intrinsic apoptotic pathway

[0084] Bcl-2 family proteins directly control the permeability of mitochondrial membranes, and they are central regulators of caspase activation. The relative members of this family, anti-apoptotic and pro-apoptotic, determine the fate of cells. In order to detect whether EriB destroys mitochondria by acting on Bcl-2 family members, we used western blot and RT-PCR to detect the anti-apoptotic factors Bcl-2 and Bcl in Kasumi-1 cells treated with EriB for 24 and 48 hours -X L And the expression of pro-apoptotic factor Bax. Bcl-2 and Bcl-X L There was a reduction at both protein and mRNA levels, however Bax expression did not change significantly (see Figure 3A and Figure 3B ). Finally, EriB induces Bcl-2 / Bax and Bcl-X L Negative regulation of the / Bax ratio (see Figure 3C and Figure 3D ), which is consistent with the result that the mitochondrial stability is disrupted d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An application of eriocalyxin B in preparing the medicines for treating acute leukemia and Burkitt's lymphoma is disclosed.

Description

technical field [0001] The present invention relates to the use of eriocetin, in particular to the application in the field of pharmacy. Background technique [0002] Acute myeloid leukemia (AML) is a group of hematopoietic malignancies originating from abnormal proliferation, differentiation and survival of myeloid progenitor cells. Specific chromosomal translocations occur frequently in AML and play an important role in the pathogenesis of leukemia. In AML, t(8;21)(q22;q22) represents the most common chromosomal translocation that generates the AML1-ETO fusion protein. AML1-ETO blocks myeloid cell differentiation and apoptosis and is involved in leukemogenesis. Clinically, 40%-50% of t(8;21) AML patients still relapse after receiving chemotherapy and develop drug resistance. Moreover, high-dose chemotherapy drugs are not suitable for elderly patients. Therefore, it is highly desirable to develop an alternative drug that can directly target the genetic changes of this t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P35/00
CPCA61K31/352A61P35/00A61P35/02
Inventor 陈赛娟陈竺王兰赵维莅孙汉董
Owner KUNMING INST OF BOTANY - CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap